All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Bookmark this article
On the 21 January 2018, Sylvain Carras, from the Hematology Department of Grenoble University Hospital, France, and the GOELAMS group, had the results of their phase II multicenter study (NCT00920153) published advanced online in the Journal of Clinical Lymphoma, Myeloma & Leukemia. The study assessed interventional treatment strategies based on interim PET imaging results, for advanced stage Hodgkin lymphoma.
With the current medical improvements, the management of Hodgkin lymphoma (HL) is considered as standard practice for most patients but still fails to cure 20-30% of patients with advanced stage HL. The aim of this study was to assess the efficacy and safety of adaptive front- and second-line treatment strategies based on interim 18F-fluorodeoxyglucose positron emission tomography (18FFDG-PET) responses, in patients with advanced stage HL. The primary endpoints of the study included event-free survival (EFS), overall survival (OS) and safety.
The authors concluded that adapting the treatment strategy, depending on the results of interim PET scanning, could be beneficial for the management of advanced stage HL. They also demonstrated the efficacy of sequential therapy with chemotherapy and ASCT in high-risk HL patients. According to the authors, despite the high and constant VABEM-related toxicity, their adapted strategy made the treatment manageable, with only a small percentage of treatment-related deaths (6%). Nevertheless, they reported that a longer-follow up study is necessary for the assessment of late toxicity. The authors proposed that this strategy should be targeted at high-risk advanced stage HL patients with positive interim PET findings, following fist-line chemotherapy.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox